# Targeting the epidermal growth factor receptor using IgM antibodies: toward next generation cancer immunotherapy

## TL;DR

This paper explores IgM antibodies as a new type of cancer treatment that may overcome current limitations of IgG-based therapies.

## Contribution

The study introduces IgM antibodies as a novel therapeutic scaffold with enhanced binding and durability for cancer immunotherapy.

## Key findings

- IgM antibodies show higher binding avidity and prolonged receptor engagement compared to IgG.
- Structural modeling reveals IgM's rigid Fc core and mobile Fab domains enable multivalent EGFR binding.
- IgM antibodies exhibit slower dissociation kinetics, suggesting improved therapeutic durability.

## Abstract

Immunoglobulin G (IgG) monoclonal antibodies dominate current cancer immunotherapy but face challenges including resistance development, limited tumor penetration, and suboptimal avidity. In contrast, the pentameric or hexameric architecture of immunoglobulin M (IgM) offers up to twelve antigen-binding sites and potent complement activation, positioning IgM as a promising next-generation therapeutic scaffold. Here, we present integrative structural modeling and multiscale molecular dynamics simulations of IgM versions of Cetuximab and Matuzumab targeting the epidermal growth factor receptor (EGFR), a clinically validated oncogenic driver. Our analyses reveal that IgM antibodies maintain a rigid, glycan-stabilized Fc core while their Fab domains exhibit high mobility, enabling multivalent EGFR binding. Compared with IgG, IgM antibodies demonstrated enhanced binding avidity, prolonged receptor engagement, and slower dissociation kinetics. These properties suggest superior therapeutic durability and potential to overcome current limitations of IgG-based therapies. By providing mechanistic insight into how IgM isotypes can improve therapeutic engagement with tumor-associated antigens, our study supports the development of IgM antibodies as a new class of cancer immunotherapies.